盐酸多奈哌齐联合左旋多巴治疗帕金森病的效果和安全性分析  

Analysis of the Efficacy and Safety of Donepezil Hydrochloride Combined with Levodopa in the Treatment of Parkinson's Disease

作　　者：聂靖炜 轩林 NIE Jingwei;XUAN Lin(Yankuang New Journey General Hospital,Jining,Shandong Province,273500 China)

机构地区：[1]兖矿新里程总医院,山东济宁273500

出　　处：《中外医疗》2023年第12期131-134,共4页China & Foreign Medical Treatment

摘　　要：目的分析帕金森病患者接受盐酸多奈哌齐联合左旋多巴治疗的临床疗效及用药安全性。方法方便择取兖矿新里程总医院2019年5月—2021年6月期间收治的帕金森病患者64例为研究对象,按随机数表法分为两组,每组32例。对照组患者接受左旋多巴治疗,观察组患者接受盐酸多奈哌齐联合左旋多巴治疗,对比两组疗效。结果观察组治疗后MMSE评分、ADL评分、MoCA评分均高于对照组,且UPDRS评分低于对照组,差异有统计学意义(t=5.007、2.693、5.006、5.489,P<0.05)。观察组治疗后超氧化物歧化酶较对照组更高,且丙二醛较对照组更低,差异有统计学意义(t=3.685、2.761,P<0.05)。观察组临床总疗效为96.88%较对照组更高,差异有统计学意义(χ^(2)=4.654,P<0.05)。观察组不良反应发生率为6.25%较对照组更低,差异有统计学意义(χ^(2)=5.379,P<0.05)。结论使用左旋多巴治疗帕金森病患者的同时,配合盐酸多奈哌齐共同治疗,可显著提升治疗效果,且安全性良好。Objective To analyze the clinical efficacy and medication safety of patients with Parkinson's disease treated with donepezil hydrochloride combined with levodopa.Methods 64 patients with Parkinson's disease admitted to Yankuang New Journey General Hospital from May 2019 to June 2021 were conveniently selected as the study objects and divided into two groups according to random number table method,with 32 patients in each group.The control group received levodopa treatment,and the observation group received Donepezil hydrochloride combined with levodopa treatment,and the efficacy of the two control groups.Results After treatment,MMSE score,ADL score and MoCA score in observation group were higher than those in control group,and UPDRS score was lower than that in control group,the difference was statistically significant(t=5.007,2.693,5.006,5.489,P<0.05).After treatment,the superoxide dismutase in the observation group was higher than that in the control group,and the malondialdehyde was lower than that in the control group,the difference was statistically significant(t=3.685,2.761,P<0.05).Clinical observation group total effectiveness is 96.88%higher than the control group,the difference was statistically significant(χ^(2)=4.654,P<0.05).Observation group,the incidence of adverse reactions was 6.25%lower than the control group,the difference was statistically significant(χ^(2)=5.379,P<0.05).Conclusion Levodopa combined with Donepezil hydrochloride in the treatment of Parkinson's disease can significantly improve the therapeutic effect and safety.

关 键 词：帕金森病 左旋多巴 盐酸多奈哌齐 安全性 临床疗效 

分 类 号：R5[医药卫生—内科学]